Work

Novel Substituted Tetrahydropyrrolooxazolones as RIPK1 Inhibitors

Year: 2026

Type: editorial

Abstract: This patent discloses tetrahydropyrrolooxazolones as novel receptor-interacting protein kinase 1 (RIPK1) inhibitors as potential treatments for RIPK1-related diseases. It provides details in the synthesis of the tetrahydropyrrolooxazolones, pharmaceutical compositions, and therapeutic applications for RIPK1-related diseases.

Source: ACS Medicinal Chemistry Letters

DOI: 10.1021/acsmedchemlett.6c00188

Authors: Jian Rong, Steven H. Liang

Institutions: Emory University, Wuhan Union Hospital, Huazhong University of Science and Technology

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W7155067392

Cites: 6

Cited by:

Related to: